Terumo’s PLAJEXᵀᴹ Provides a Solution for a New Osteoporosis Treatment Developed and Manufactured on Contract
TOKYO, JAPAN – December 11, 2019 – Terumo Corporation (TSE: 4543) today announced that a new osteoporosis medication, TeriboneTM 28.2μg subcutaneous autoinjector, has been launched in the Japanese market for patients with a high risk of fractures. Terumo has signed a development and manufacturing contract with Asahi Kasei Pharma Corporation. The product will be manufactured at Terumo Yamaguchi D&D Corporation and marketed by Asahi Kasei Pharma.
Asahi Kasei Pharma has been providing lyophilized vial formulation TeriboneTM 56.5μg subcutaneous injection, since 2011. This new product offers a new treatment option for patients. The product design enables patients to easily self-inject in a home setting.
TeriboneTM 28.2μg is pre-filled in Terumo’s PLAJEXTM silicone oil-free syringe. The highly breakage-resistant polymer material and the low-reactive and stable characteristic of the syringe played a role in the design of this new product, which is safe for self-injection. The product is assembled with a 2-step autoinjector. Patients simply remove the cap and press the device onto the skin to complete the injection. The single dose use medication is also suitable for elderly patients on continual treatment.
Terumo will continue to strive for the expansion of their CDMO (Contract Development and Manufacturing Organization) business to provide new solutions for pharmaceutical companies, and so contribute to better healthcare.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.